Rationale in use of LHRH analogues in endometriosis

R W Shaw, Shaw RW
Hormone research · 1989 · doi:10.1159/000181322 · PMID:2533143
other OA: closed public-domain-us
View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-12 ⓘ

This paper discusses the rationale for using LHRH analogues as a potential hormonal treatment for endometriosis, noting promising results despite limitations caused by drug side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

In addition to surgery, several hormonal treatments are available for endometriosis. Although efficacious, drug treatment is limited by side effects. Recent work with LHRH analogues as a potential treatment for endometriosis has shown promising results.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gonadotropin-Releasing Hormone Buserelin Buserelin Buserelin Danazol Danazol Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Goserelin Humans Nafarelin

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-21T06:08:07.822426+00:00
pubmed
last seen: 2026-05-13T22:09:15.954262+00:00
unpaywall
last seen: 2026-09-22T06:12:16.469521+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine